Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.48 |
| ▸ | VDR | P11473 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744980 | 0.89 | FFAR1 (0.61) | FFAR1PPARDFFAR4 | |
| SCHEMBL1746718 | 0.80 | FFAR1 (0.62) | FFAR1VDRPPARDFFAR4 | |
| SCHEMBL1744706 | 0.79 | ADRB2 (0.47) | FFAR1VDRPPARDFFAR4ADRB2 | |
| SCHEMBL1747205 | 0.77 | FFAR1 (0.79) | FFAR1FFAR4 | |
| SCHEMBL1745358 | 0.76 | FFAR1 (0.79) | FFAR1VDRPPARDFFAR4 | |
| SCHEMBL28388911 | 0.76 | FFAR1 (0.80) | FFAR1VDRPPARDRPS6KB2FFAR4 | |
| SCHEMBL1744704 | 0.75 | FFAR1 (0.51) | FFAR1VDRPPARDFFAR4ADRB2 | |
| SCHEMBL1744946 | 0.75 | FFAR1 (0.56) | FFAR1VDRPPARDFFAR4 | |
| SCHEMBL1747394 | 0.75 | FFAR1 (0.82) | FFAR1VDRPPARDFFAR4 | |
| SCHEMBL12646512 | 0.74 | FFAR1 (0.54) | FFAR1VDRPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | FFAR1 33/4885VDR 117/4885PPARD 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.